APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Relapsed Acute Myeloid Leukemia Drug

Compare research editions
View pricing & licenses

Selected research

Industry Research

Relapsed Acute Myeloid Leukemia Drug Industry Research Report 2026

Report ID 174032120519 December 2025139 pages

Choose your research edition.

Industry ResearchRelapsed Acute Myeloid Leukemia Drug Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Relapsed Acute Myeloid Leukemia Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Relapsed Acute Myeloid Leukemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Relapsed Acute Myeloid Leukemia Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Relapsed Acute Myeloid Leukemia Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Relapsed Acute Myeloid Leukemia Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Relapsed Acute Myeloid Leukemia Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Relapsed Acute Myeloid Leukemia Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Relapsed Acute Myeloid Leukemia Drug include 4SC AG, Amgen Inc., AbbVie Inc., AstraZeneca Plc, CTI BioPharma Corp., Cornerstone Pharmaceuticals, Inc., Celgene Corporation, Calithera Biosciences, Inc. and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Relapsed Acute Myeloid Leukemia Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Relapsed Acute Myeloid Leukemia Drug Market by Company

4SC AG

Amgen Inc.

AbbVie Inc.

AstraZeneca Plc

CTI BioPharma Corp.

Cornerstone Pharmaceuticals, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

Bristol-Myers Squibb Company

Boston Biomedical, Inc.

Boehringer Ingelheim GmbH

BioLineRx, Ltd.

AVEO Pharmaceuticals, Inc.

Astex Pharmaceuticals, Inc.

Astellas Pharma Inc.

Array BioPharma Inc.

Arog Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Relapsed Acute Myeloid Leukemia Drug Segment by Type

aNK Program

AT-9283

BI-836858

BL-8040

Binimetinib

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Application

Clinic

Hospital

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Relapsed Acute Myeloid Leukemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Relapsed Acute Myeloid Leukemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Relapsed Acute Myeloid Leukemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Relapsed Acute Myeloid Leukemia Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Relapsed Acute Myeloid Leukemia Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Relapsed Acute Myeloid Leukemia Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Relapsed Acute Myeloid Leukemia Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Relapsed Acute Myeloid Leukemia Drug Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers (2021-2026) Table 8. Global Relapsed Acute Myeloid Leukemia Drug Revenue of Manufacturers (2021-2026) Table 9. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Relapsed Acute Myeloid Leukemia Drug Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Relapsed Acute Myeloid Leukemia Drug Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Product Type & Application Table 14. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Relapsed Acute Myeloid Leukemia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. 4SC AG Company Information Table 19. 4SC AG Business Overview Table 20. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 22. 4SC AG Recent Developments Table 23. Amgen Inc. Company Information Table 24. Amgen Inc. Business Overview Table 25. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 27. Amgen Inc. Recent Developments Table 28. AbbVie Inc. Company Information Table 29. AbbVie Inc. Business Overview Table 30. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 32. AbbVie Inc. Recent Developments Table 33. AstraZeneca Plc Company Information Table 34. AstraZeneca Plc Business Overview Table 35. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 37. AstraZeneca Plc Recent Developments Table 38. CTI BioPharma Corp. Company Information Table 39. CTI BioPharma Corp. Business Overview Table 40. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 42. CTI BioPharma Corp. Recent Developments Table 43. Cornerstone Pharmaceuticals, Inc. Company Information Table 44. Cornerstone Pharmaceuticals, Inc. Business Overview Table 45. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 47. Cornerstone Pharmaceuticals, Inc. Recent Developments Table 48. Celgene Corporation Company Information Table 49. Celgene Corporation Business Overview Table 50. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 52. Celgene Corporation Recent Developments Table 53. Calithera Biosciences, Inc. Company Information Table 54. Calithera Biosciences, Inc. Business Overview Table 55. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 57. Calithera Biosciences, Inc. Recent Developments Table 58. Bristol-Myers Squibb Company Company Information Table 59. Bristol-Myers Squibb Company Business Overview Table 60. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 62. Bristol-Myers Squibb Company Recent Developments Table 63. Boston Biomedical, Inc. Company Information Table 64. Boston Biomedical, Inc. Business Overview Table 65. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 67. Boston Biomedical, Inc. Recent Developments Table 68. Boehringer Ingelheim GmbH Company Information Table 69. Boehringer Ingelheim GmbH Business Overview Table 70. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 72. Boehringer Ingelheim GmbH Recent Developments Table 73. BioLineRx, Ltd. Company Information Table 74. BioLineRx, Ltd. Business Overview Table 75. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 77. BioLineRx, Ltd. Recent Developments Table 78. AVEO Pharmaceuticals, Inc. Company Information Table 79. AVEO Pharmaceuticals, Inc. Business Overview Table 80. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 82. AVEO Pharmaceuticals, Inc. Recent Developments Table 83. Astex Pharmaceuticals, Inc. Company Information Table 84. Astex Pharmaceuticals, Inc. Business Overview Table 85. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 87. Astex Pharmaceuticals, Inc. Recent Developments Table 88. Astellas Pharma Inc. Company Information Table 89. Astellas Pharma Inc. Business Overview Table 90. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 92. Astellas Pharma Inc. Recent Developments Table 93. Array BioPharma Inc. Company Information Table 94. Array BioPharma Inc. Business Overview Table 95. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 97. Array BioPharma Inc. Recent Developments Table 98. Arog Pharmaceuticals, Inc. Company Information Table 99. Arog Pharmaceuticals, Inc. Business Overview Table 100. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 102. Arog Pharmaceuticals, Inc. Recent Developments Table 103. Agios Pharmaceuticals, Inc. Company Information Table 104. Agios Pharmaceuticals, Inc. Business Overview Table 105. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 107. Agios Pharmaceuticals, Inc. Recent Developments Table 108. Actinium Pharmaceuticals, Inc. Company Information Table 109. Actinium Pharmaceuticals, Inc. Business Overview Table 110. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 112. Actinium Pharmaceuticals, Inc. Recent Developments Table 113. Global Relapsed Acute Myeloid Leukemia Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026) & (K Units) Table 115. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2021-2026) Table 116. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2027-2032) & (K Units) Table 117. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2027-2032) Table 118. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2021-2026) & (US$ Million) Table 119. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2021-2026) Table 120. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2027-2032) & (US$ Million) Table 121. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2027-2032) Table 122. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 124. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 125. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 126. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 129. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 130. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 137. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 139. South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 140. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 141. South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2027-2032) & (US$ Million) Table 147. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 148. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 149. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2026) Table 150. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2027-2032) Table 151. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2026) Table 154. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2027-2032) Table 155. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2026) & (US$/Unit) Table 156. Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2027-2032) & (US$/Unit) Table 157. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 158. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 159. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2026) Table 160. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2027-2032) Table 161. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (US$ Million) Table 162. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2027-2032) & (US$ Million) Table 163. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2026) Table 164. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2027-2032) Table 165. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2026) & (US$/Unit) Table 166. Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. Relapsed Acute Myeloid Leukemia Drug Distributors List Table 170. Relapsed Acute Myeloid Leukemia Drug Customers List Table 171. Relapsed Acute Myeloid Leukemia Drug Industry Trends Table 172. Relapsed Acute Myeloid Leukemia Drug Industry Drivers Table 173. Relapsed Acute Myeloid Leukemia Drug Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Relapsed Acute Myeloid Leukemia Drug Product Image Figure 5. Global Relapsed Acute Myeloid Leukemia Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Relapsed Acute Myeloid Leukemia Drug Market Size (2021-2032) & (US$ Million) Figure 7. Global Relapsed Acute Myeloid Leukemia Drug Sales (2021-2032) & (K Units) Figure 8. Global Relapsed Acute Myeloid Leukemia Drug Average Price (US$/Unit) & (2021-2032) Figure 9. aNK Program Product Image Figure 10. AT-9283 Product Image Figure 11. BI-836858 Product Image Figure 12. BL-8040 Product Image Figure 13. Binimetinib Product Image Figure 14. Others Product Image Figure 15. Clinic Product Image Figure 16. Hospital Product Image Figure 17. Others Product Image Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers in 2025 Figure 19. Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Manufacturing Sites & Headquarters Figure 20. Global Top 5 and 10 Relapsed Acute Myeloid Leukemia Drug Players Market Share by Revenue in 2025 Figure 21. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Relapsed Acute Myeloid Leukemia Drug Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 23. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region in 2025 Figure 24. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region in 2025 Figure 25. North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country in 2025 Figure 26. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 27. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2021-2032) Figure 28. United States Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Canada Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country in 2025 Figure 31. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 32. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2021-2032) Figure 33. Germany Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Country in 2025 Figure 39. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 40. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2021-2032) Figure 41. China Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Japan Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. South Korea Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. India Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Australia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. China Taiwan Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. South America Relapsed Acute Myeloid Leukemia Drug Market Size by Country in 2025 Figure 50. South America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 51. South America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2021-2032) Figure 52. Mexico Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Brazil Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Argentina Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Colombia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country in 2025 Figure 57. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 58. Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Country (2021-2032) Figure 59. Turkey Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. UAE Relapsed Acute Myeloid Leukemia Drug Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2032) Figure 63. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2032) Figure 64. Global Relapsed Acute Myeloid Leukemia Drug Price (US$/Unit) by Type (2021-2032) Figure 65. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2032) Figure 66. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2032) Figure 67. Global Relapsed Acute Myeloid Leukemia Drug Price (US$/Unit) by Application (2021-2032) Figure 68. Relapsed Acute Myeloid Leukemia Drug Value Chain Figure 69. Relapsed Acute Myeloid Leukemia Drug Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges

Scope & coverage.

Types
  • aNK Program
  • AT-9283
  • BI-836858
  • BL-8040
  • Binimetinib
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • 4SC AG
  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca Plc
  • CTI BioPharma Corp.
  • Cornerstone Pharmaceuticals, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Boston Biomedical, Inc.
  • Boehringer Ingelheim GmbH
  • BioLineRx, Ltd.
  • AVEO Pharmaceuticals, Inc.
  • Astex Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Array BioPharma Inc.
  • Arog Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size (2021-2032)
  4. 2.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales (2021-2032)
  5. 2.2.3 Global Relapsed Acute Myeloid Leukemia Drug Market Average Price (2021-2032)
  6. 2.3 Relapsed Acute Myeloid Leukemia Drug by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 aNK Program
  9. 2.3.3 AT-9283
  10. 2.3.4 BI-836858
  11. 2.3.5 BL-8040
  12. 2.3.6 Binimetinib
  13. 2.3.7 Others
  14. 2.4 Relapsed Acute Myeloid Leukemia Drug by Application
  15. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  16. 2.4.2 Clinic
  17. 2.4.3 Hospital
  18. 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Relapsed Acute Myeloid Leukemia Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Relapsed Acute Myeloid Leukemia Drug Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Relapsed Acute Myeloid Leukemia Drug Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Relapsed Acute Myeloid Leukemia Drug Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Product Type & Application
  8. 3.8 Global Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Established Date
  9. 3.9 Global Relapsed Acute Myeloid Leukemia Drug Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 4SC AG
  2. 4.1.1 4SC AG Company Information
  3. 4.1.2 4SC AG Business Overview
  4. 4.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  6. 4.1.5 4SC AG Recent Developments
  7. 4.2 Amgen Inc.
  8. 4.2.1 Amgen Inc. Company Information
  9. 4.2.2 Amgen Inc. Business Overview
  10. 4.2.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  12. 4.2.5 Amgen Inc. Recent Developments
  13. 4.3 AbbVie Inc.
  14. 4.3.1 AbbVie Inc. Company Information
  15. 4.3.2 AbbVie Inc. Business Overview
  16. 4.3.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  18. 4.3.5 AbbVie Inc. Recent Developments
  19. 4.4 AstraZeneca Plc
  20. 4.4.1 AstraZeneca Plc Company Information
  21. 4.4.2 AstraZeneca Plc Business Overview
  22. 4.4.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  24. 4.4.5 AstraZeneca Plc Recent Developments
  25. 4.5 CTI BioPharma Corp.
  26. 4.5.1 CTI BioPharma Corp. Company Information
  27. 4.5.2 CTI BioPharma Corp. Business Overview
  28. 4.5.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  30. 4.5.5 CTI BioPharma Corp. Recent Developments
  31. 4.6 Cornerstone Pharmaceuticals, Inc.
  32. 4.6.1 Cornerstone Pharmaceuticals, Inc. Company Information
  33. 4.6.2 Cornerstone Pharmaceuticals, Inc. Business Overview
  34. 4.6.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  36. 4.6.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
  37. 4.7 Celgene Corporation
  38. 4.7.1 Celgene Corporation Company Information
  39. 4.7.2 Celgene Corporation Business Overview
  40. 4.7.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  42. 4.7.5 Celgene Corporation Recent Developments
  43. 4.8 Calithera Biosciences, Inc.
  44. 4.8.1 Calithera Biosciences, Inc. Company Information
  45. 4.8.2 Calithera Biosciences, Inc. Business Overview
  46. 4.8.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  48. 4.8.5 Calithera Biosciences, Inc. Recent Developments
  49. 4.9 Bristol-Myers Squibb Company
  50. 4.9.1 Bristol-Myers Squibb Company Company Information
  51. 4.9.2 Bristol-Myers Squibb Company Business Overview
  52. 4.9.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  54. 4.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 4.10 Boston Biomedical, Inc.
  56. 4.10.1 Boston Biomedical, Inc. Company Information
  57. 4.10.2 Boston Biomedical, Inc. Business Overview
  58. 4.10.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  60. 4.10.5 Boston Biomedical, Inc. Recent Developments
  61. 4.11 Boehringer Ingelheim GmbH
  62. 4.11.1 Boehringer Ingelheim GmbH Company Information
  63. 4.11.2 Boehringer Ingelheim GmbH Business Overview
  64. 4.11.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  66. 4.11.5 Boehringer Ingelheim GmbH Recent Developments
  67. 4.12 BioLineRx, Ltd.
  68. 4.12.1 BioLineRx, Ltd. Company Information
  69. 4.12.2 BioLineRx, Ltd. Business Overview
  70. 4.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  72. 4.12.5 BioLineRx, Ltd. Recent Developments
  73. 4.13 AVEO Pharmaceuticals, Inc.
  74. 4.13.1 AVEO Pharmaceuticals, Inc. Company Information
  75. 4.13.2 AVEO Pharmaceuticals, Inc. Business Overview
  76. 4.13.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  78. 4.13.5 AVEO Pharmaceuticals, Inc. Recent Developments
  79. 4.14 Astex Pharmaceuticals, Inc.
  80. 4.14.1 Astex Pharmaceuticals, Inc. Company Information
  81. 4.14.2 Astex Pharmaceuticals, Inc. Business Overview
  82. 4.14.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  84. 4.14.5 Astex Pharmaceuticals, Inc. Recent Developments
  85. 4.15 Astellas Pharma Inc.
  86. 4.15.1 Astellas Pharma Inc. Company Information
  87. 4.15.2 Astellas Pharma Inc. Business Overview
  88. 4.15.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  90. 4.15.5 Astellas Pharma Inc. Recent Developments
  91. 4.16 Array BioPharma Inc.
  92. 4.16.1 Array BioPharma Inc. Company Information
  93. 4.16.2 Array BioPharma Inc. Business Overview
  94. 4.16.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  96. 4.16.5 Array BioPharma Inc. Recent Developments
  97. 4.17 Arog Pharmaceuticals, Inc.
  98. 4.17.1 Arog Pharmaceuticals, Inc. Company Information
  99. 4.17.2 Arog Pharmaceuticals, Inc. Business Overview
  100. 4.17.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  102. 4.17.5 Arog Pharmaceuticals, Inc. Recent Developments
  103. 4.18 Agios Pharmaceuticals, Inc.
  104. 4.18.1 Agios Pharmaceuticals, Inc. Company Information
  105. 4.18.2 Agios Pharmaceuticals, Inc. Business Overview
  106. 4.18.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  108. 4.18.5 Agios Pharmaceuticals, Inc. Recent Developments
  109. 4.19 Actinium Pharmaceuticals, Inc.
  110. 4.19.1 Actinium Pharmaceuticals, Inc. Company Information
  111. 4.19.2 Actinium Pharmaceuticals, Inc. Business Overview
  112. 4.19.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  114. 4.19.5 Actinium Pharmaceuticals, Inc. Recent Developments
5 Global Relapsed Acute Myeloid Leukemia Drug Market Scenario by Region
  1. 5.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021-2032
  3. 5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021-2026
  4. 5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2027-2032
  5. 5.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2021-2032
  6. 5.3.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2021-2026
  7. 5.3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2027-2032
  8. 5.4 North America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
  9. 5.4.1 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  11. 5.4.3 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
  15. 5.5.1 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  17. 5.5.3 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
  35. 5.7.1 South America Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  37. 5.7.3 South America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.7.7 Colombia
  42. 5.8 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Facts & Figures by Country
  43. 5.8.1 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Market Size by Country: 2021 VS 2025 VS 2032
  44. 5.8.2 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  45. 5.8.3 Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2021-2032)
  46. 5.8.4 Turkey
  47. 5.8.5 Saudi Arabia
  48. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032)
  2. 6.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2032)
  4. 6.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2032)
  5. 6.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032)
  2. 7.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2032)
  4. 7.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2032)
  5. 7.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Relapsed Acute Myeloid Leukemia Drug Value Chain Analysis
  2. 8.1.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Relapsed Acute Myeloid Leukemia Drug Production Mode & Process
  5. 8.2 Relapsed Acute Myeloid Leukemia Drug Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Relapsed Acute Myeloid Leukemia Drug Distributors
  8. 8.2.3 Relapsed Acute Myeloid Leukemia Drug Customers
9 Global Relapsed Acute Myeloid Leukemia Drug Analyzing Market Dynamics
  1. 9.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
  2. 9.2 Relapsed Acute Myeloid Leukemia Drug Industry Drivers
  3. 9.3 Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges
  4. 9.4 Relapsed Acute Myeloid Leukemia Drug Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst